DUBLIN--(BUSINESS WIRE)--The "Global Pneumococcal Vaccine Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
The global pneumococcal vaccine market is expected to grow at a CAGR of 6.17% to reach a total market size of US$10.436 billion by 2023, increasing from US$7.287 billion in 2017.
Rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, sinusitis, bronchitis and others is driving the demand for pneumococcal vaccines. According to WHO, pneumococcal vaccine had been introduced in 134 countries by 2016 end and estimated global coverage was about 42%. Growing awareness regarding the importance of vaccination and increasing spending by the governments towards public health is fuelling the development of pneumococcal vaccines in the developing countries. Major market players in the global pneumococcal vaccine market are Pfizer, Sanofi, GSK, Merck, AstraZeneca and Baxter International.
On the basis of type, pneumococcal vaccine market is segmented as conjugate vaccines and polysaccharide vaccines. Out of these two, conjugate vaccines are more robust as compared to the polysaccharide ones and hence have a significant market share.
In terms of geography, global pneumococcal vaccine segmentation includes North America, South America, Europe, Middle East and Africa, and Asia-Pacific. Rising awareness programmes regarding the proper vaccination is driving the market growth in developing and underdeveloped countries.
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Global Pneumococcal Vaccine Market Forecast by Type (US$ Billion)
6. Global Pneumococcal Vaccine Market Forecast by Method (US$ Billion)
7. Global Pneumococcal Vaccine Market Forecast by Geography (US$ Billion)
8. Competitive Intelligence
9. Company Profiles
- Sanofi Pasteur MSD
- Baxter International
For more information about this report visit https://www.researchandmarkets.com/research/2z6hvn/global?w=4